Arina, A., O. Murillo, S. Hervas-Stubbs, A. Azpilikueta, J. Dubrot, I. Tirapu, E. Huarte, C. Alfaro, J. L. Perez-Gracia, G. Gonzalez-Aseguinolaza, P. Sarobe, J. J. Lasarte, A. Jamieson, J. Prieto, D. H. Raulet, and I. Melero. 2007. The combined actions of NK and T lymphocytes are necessary to reject an EGFP+ mesenchymal tumor through mechanisms dependent on NKG2D and IFNgamma. Int J Cancer 121(6): 1282-195.
Arimidex’ (anastrozole): The Ideal Profile for an
ARIMIDEX® (anastrozole) in the Treatment of Early Breast Cancer
Arimidex (Breast Cancer) - Analysis and Forecasts to 2020 Brochure
Aries Sagittarius Lion Capricorn Taurus Fish Daily Horoscope Leo
Ariella Shikanov, Ph.D. - The Hartwell Foundation
ARIEL2: A phase 2 study to prospectively respond to rucaparib
ARID1A Mutations in Cancer: Another Epigenetic Tumor Suppressor?
Arial Narrow 28pt. Office of Education Primary Care Update in Urology
Ariadne Genomics technology
Argonaute-2 Expression Is Regulated by Epidermal Growth Factor
Areca Nut Use and Cancer in India
area cancer control network: from cottage industry to strategic care
are you at risk of skin cancer? - The Australasian College of
Are You at Risk for Ovarian Cancer?
Are We Truly winning the War On Cancer?
Are we sleeping on the job? Insomnia among men with prostate
Are Triple-Negative and Basal-Like Breast Cancer Synonymous?
Are there useable molecular markers for prostate cancer?
Are there disparities in childhood cancer?
Are there any complementary and alternative medicines that should
